The July 25-29 AACC (American Association of Clinical Chemistry) Meeting in Anaheim will have close to 20,000 clinical lab professionals and over 500 exhibitors. A stock rally in the sector was ignited last week by earnings announcements Read more…
ACTC.OB has submitted documentation and a complete response to substantively address the issues raised by the FDA in connection with their plans to initiate a Phase I/II multicenter study using embryonic stem (ES) cell derived retinal cells to treat patients with Stargardt’s Macular Dystrophy (SMD). Read more…
CYTX received expanded European approval (CE Mark) for its Celution® System, a medical device that extracts and separates stem and regenerative cells from a patient’s own fat tissue. Read more…
CYTX expanded its Celution® System CE Mark by receiving additional indications-for-use, which build upon the existing device approval. Read more…
ISCO entered into a Memorandum of Understanding with ARG Vermogensverwaltung AG (‘ARG’), a German Investment Fund, to create a new European subsidiary (‘ISCO Europe’) to be funded with up to $10 M of capital Read more…
BTIM will be offering (8/1/10) for sale; 21 new stem cell products for research use only. Read more…
The Australian Therapeutic Goods Administration (TGA) has issued a license to Mesoblast to manufacture and supply its proprietary Mesenchymal Precursor Cell (MPC) products. Read more…
ISCO and Insight BioVentures India Private Limited (IBVI) have signed a letter of intent concerning funding and establishment of an Indian affiliate, ISCO India. Read more…
The Biologics and Genetic Therapies Directorate of Health Canada has completed its initial evaluation and accepted for full review OSIR’s New Drug Submission (NDS) of Prochymal (remestemcel-L),
A new analyst review of Cytori Therapeutics. (NASDAQ:CYTX) entitled, “Targeting Ischemic Diseases by Improving Blood Flow.” Read more…
Founder and Director of Research, Henry McCusker enters his eighth (8) year at Scimitar Equity with past experience in sell-side analysis, buy-side management, corporate management and due diligence.